PMID- 34646327
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20230630
IS  - 1741-427X (Print)
IS  - 1741-4288 (Electronic)
IS  - 1741-427X (Linking)
VI  - 2021
DP  - 2021
TI  - Influence of Different Antiepileptic Drugs on Blood Ammonia and Homocysteine 
      Levels in Children with Epilepsy.
PG  - 5698765
LID - 10.1155/2021/5698765 [doi]
LID - 5698765
AB  - In this study, we performed a study on 106 children with epilepsy who were 
      treated with sodium valproate (the VPA group, n = 37), oxcarbazepine (the OXC 
      group, n = 34), or levetiracetam (the LEV group, n = 35). In addition, the 
      clinical data of epileptic children who were newly diagnosed in the same period 
      without antiepileptic drug (AED) treatment (the untreated group, n = 35) and 
      normal children who received physical examination in our hospital (the healthy 
      group, n = 35) were selected as controls. We analyzed the efficacy and safety of 
      different AEDs, used blood ammonia and homocysteine levels as the observation 
      indicators, and calculated the incidence of hyperammonemia (VAH) and 
      hyperhomocysteinemia (HHcy) treated with different AEDs. And, based on the effect 
      of epilepsy status on the cognitive function of patients, we also analyzed the 
      effect of different AED treatments on children's cognitive function. Our results 
      show that sodium valproate, oxcarbazepine, and levetiracetam are all effective in 
      the treatment of children with epilepsy and can be used as the first-line choice 
      of antiepileptic treatment for children with epilepsy. However, compared with 
      sodium valproate, levetiracetam and oxcarbazepine have a lower incidence of 
      adverse drug reactions and do not cause an increase in blood ammonia and Hcy 
      levels, so they have higher safety of drug treatment. In addition, compared with 
      sodium valproate, levetiracetam and oxcarbazepine have better recovery of 
      cognitive function in children with epilepsy and so they have better application 
      value.
CI  - Copyright (c) 2021 Meng Sun et al.
FAU - Sun, Meng
AU  - Sun M
AUID- ORCID: 0000-0001-6513-0891
AD  - Department of Pediatrics, Hebei General Hospital, Shijiazhuang, Heibei 050051, 
      China.
FAU - Zhou, Ran
AU  - Zhou R
AD  - Department of Pediatrics, Hebei General Hospital, Shijiazhuang, Heibei 050051, 
      China.
FAU - Wang, Xin
AU  - Wang X
AD  - Department of Pediatrics, Hebei General Hospital, Shijiazhuang, Heibei 050051, 
      China.
FAU - Cheng, Yaying
AU  - Cheng Y
AUID- ORCID: 0000-0001-8889-3509
AD  - Department of Pediatrics, Hebei General Hospital, Shijiazhuang, Heibei 050051, 
      China.
LA  - eng
PT  - Journal Article
PT  - Retracted Publication
DEP - 20211004
PL  - United States
TA  - Evid Based Complement Alternat Med
JT  - Evidence-based complementary and alternative medicine : eCAM
JID - 101215021
RIN - Evid Based Complement Alternat Med. 2023 Jun 21;2023:9824826. PMID: 37387898
PMC - PMC8505063
COIS- The authors declare that they have no conflicts of interest.
EDAT- 2021/10/15 06:00
MHDA- 2021/10/15 06:01
PMCR- 2021/10/04
CRDT- 2021/10/14 06:34
PHST- 2021/08/22 00:00 [received]
PHST- 2021/09/20 00:00 [accepted]
PHST- 2021/10/14 06:34 [entrez]
PHST- 2021/10/15 06:00 [pubmed]
PHST- 2021/10/15 06:01 [medline]
PHST- 2021/10/04 00:00 [pmc-release]
AID - 10.1155/2021/5698765 [doi]
PST - epublish
SO  - Evid Based Complement Alternat Med. 2021 Oct 4;2021:5698765. doi: 
      10.1155/2021/5698765. eCollection 2021.